

# Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB)

Carl E Clarke,<sup>1,2\*</sup> Smitaa Patel,<sup>3</sup> Natalie Ives,<sup>3</sup>  
Caroline E Rick,<sup>3</sup> Rebecca Woolley,<sup>3</sup> Keith Wheatley,<sup>4</sup>  
Marion F Walker,<sup>5</sup> Shihua Zhu,<sup>6</sup> Rebecca Kandiyali,<sup>7</sup>  
Guiqing Yao<sup>7</sup> and Catherine M Sackley<sup>8,9</sup>  
on behalf of the PD REHAB Collaborative Group

<sup>1</sup>Institute for Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>2</sup>Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham, UK

<sup>3</sup>Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>4</sup>Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>5</sup>Rehabilitation and Ageing, Queen's Medical Centre, University of Nottingham, Nottingham, UK

<sup>6</sup>Primary Care Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>7</sup>Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

<sup>8</sup>University of East Anglia, Norwich, UK

<sup>9</sup>Academic Department of Physiotherapy, Faculty of Life Sciences and Medicine, King's College London, London, UK

\*Corresponding author

**Declared competing interests of authors:** Marion F Walker declares a consultancy with Allergan on long-term problems after stroke.

Published August 2016

DOI: 10.3310/hta20630

## Scientific summary

### **The PD REHAB trial**

Health Technology Assessment 2016; Vol. 20: No. 63

DOI: 10.3310/hta20630

NIHR Journals Library [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

# Scientific summary

## Background

Parkinson's disease (PD) affects over 1% of people older than 60 years and the prevalence is set to rise with the ageing population. It causes significant problems with activities of daily living (ADL) that are only partially treated by medication and occasionally surgery. Despite treatment, patients go on to develop intractable motor problems (e.g. imbalance and falls), along with mental-health problems and other non-motor symptoms.

Physiotherapy (PT) and occupational therapy (OT) are traditionally used later in the course of PD and both therapies are frequently offered together. PT aims to promote and maintain mobility and activity by treating motor impairments with exercise and task-related practice. OT works in partnership with patients to address personal rehabilitation goals through activity and participation. Both forms of therapy aim to help patients remain as independent as possible and to reduce carer strain.

Cochrane reviews of PT and OT for PD found insufficient evidence of their individual effectiveness, but previous trials were methodologically flawed with small sample size and short-term follow-up. The UK National Institute for Health and Care Excellence guidelines, although recognising these shortcomings and recommending further trials, stated that all patients should have access to both therapies.

Before commencing the PD REHAB trial, we initially performed a pilot study of OT in PD (PD OT), as considerable evidence was already available on outcome measures from PT trials in PD. PD OT provided us with invaluable information on recruitment rate, outcome measures and data to inform the sample size for the main trial.

## Objectives

The objective of the PD REHAB trial was to evaluate the clinical effectiveness and cost-effectiveness of individualised PT and OT in patients with PD.

## Methods

PD REHAB was a large pragmatic randomised controlled trial performed in 38 neurology and geriatric medicine outpatient clinics in the UK.

## Patients

We recruited patients with idiopathic PD (defined by the UK Parkinson's Disease Society Brain Bank Criteria) who had limitations in ADL. We ensured that investigators were uncertain that the patients would require PT and/or OT during the 15 months of the trial, that is that equipoise about the need for therapy existed. We excluded patients with dementia, as locally defined, and those in receipt of PT or OT for PD in the last 12 months. All patients gave written informed consent before randomisation.

### **Outcome measures**

The primary outcome was instrumental ADL measured by the Nottingham Extended Activities of Daily Living (NEADL) scale at 3 months after randomisation. Secondary outcomes were health-related quality of life [Parkinson's Disease Questionnaire-39 (PDQ-39); European Quality of Life-5 Dimensions (EQ-5D)], adverse events, and carer quality of life (Short Form questionnaire-12 items).

Outcomes were assessed before randomisation and at 3, 9 and 15 months after randomisation.

### **Intervention**

Patients were randomised (1 : 1) to combined PT and OT (therapy group) or no therapy (control group) using an online randomisation service at the Birmingham Clinical Trials Unit (BCTU), University of Birmingham. PT and OT were delivered in the community and/or outpatients clinics by qualified therapists working within the NHS. A framework for therapy content was developed and agreed by expert therapist groups based on previous work on standards of NHS PT and OT and European guidelines. Following initial assessments by both a physiotherapist and an occupational therapist, therapy was tailored to the individual patient's requirements using a joint goal-setting approach. Interactions between therapists and patients were quantified using pre-defined recording forms.

### **Sample size**

The sample size was based on detecting a 2.5-point clinically meaningful difference in the 66-point NEADL scale at 3 months, using the observed standard deviation from the PD OT pilot trial of 10.1 points with a 5% significance level and 90% power. This required 340 patients in each group, which was increased to 750 participants (375 per group) to allow for around 10% non-compliance and dropout.

### **Economic evaluation**

An incremental economic analysis was conducted from a NHS and Personal Social Services perspective. This combined prospectively collected data on resource use, costs and the important consequences in terms of quality of life (EQ-5D). We performed a cost-utility analysis over 15 months, examining the cost per quality-adjusted life-year (QALY) gained.

## **Results**

### **Recruitment**

Between October 2009 and June 2012, a total of 762 patients with mild to moderate Parkinson's disease and limitations in ADL were recruited to the study.

### **Loss to follow-up**

In total, 92% of the 381 patients randomised to the therapy arm completed the NEADL at 3 months compared with 92% of 381 patients randomised to the no therapy arm. The equivalent completion rates at 15 months were 85% in the therapy arm and 88% in the no therapy arm.

### **Therapy content**

In the therapy group, the median number of therapy sessions, including initial assessments, was four, with a mean time per session of 58 minutes. The mean duration of therapy was 8 weeks. The intervention logs provided by the therapists demonstrated an eclectic approach consistent with NHS practice.

Physiotherapists prescribed a range of exercise programmes tailored to their assessment of the patient's physical strength and range of movement. Detailed content analysis of a 10% sample revealed that only three centres provided a specific PD exercise programme accompanied by a booklet, and there was no evidence of a formal exercise progression protocol for any patient. PT included the prescription of walking aids.

Occupational therapy assessed the full range of ADL including leisure activity and work. However, the predominant interventions were equipment provision (such as bed levers or adaptive cutlery) and onward referral (such as speech and language therapy and cognitive assessment), with other advice including recommendations on how to manage sleep problems and how to apply for state benefits. At some centres there was a limit on the funding of prescribed aids; however, the trial was able to fund some of them to improve parity. There was little task-related practice.

### Effectiveness

At the primary time point of 3 months, there was no difference in NEADL total score [difference 0.5 points, 95% confidence interval (CI)  $-0.7$  to  $1.7$  points;  $p = 0.4$ ] or PDQ-39 summary index (0.007 points, 95% CI  $-1.5$  to  $1.5$  points;  $p = 1.0$ ) between groups. The EQ-5D quotient was of borderline significance in favour of therapy ( $-0.03$ , 95% CI  $-0.07$  to  $-0.002$ ;  $p = 0.04$ ).

Repeated measures analysis including all time points showed no difference in NEADL total score, but PDQ-39 summary index (curves diverging at 1.6 points per annum, 95% CI 0.47 to 2.62 points;  $p = 0.005$ ) and EQ-5D quotient (0.02, 95% CI 0.00007 to 0.03;  $p = 0.04$ ) showed significant but small differences in favour of the therapy arm.

There was no difference in adverse events or serious adverse events.

### Economic analysis

The economic analysis showed no statistically significant differences in incremental costs (£164, 95% CI  $-£141$  to £468) or QALYs (0.027 QALYs, 95% CI  $-0.010$  to 0.065 QALYs). The incremental cost per QALY was under £4000 but highly uncertain (£3493, 95% CI  $-£169,371$  to £176,358).

## Conclusions

Overall, NHS PT and OT did not produce immediate or long-term clinically meaningful improvements in ADL or quality of life in mild to moderate PD. This evidence does not support the use of low-dose, patient-centred, goal-directed PT and OT in patients in the early stages of PD. Future research should include the development and testing of more structured and intensive physical therapy programmes in patients with all stages of PD.

## Trial registration

This trial is registered as ISRCTN17452402.

## Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research. The Birmingham Clinical Trials Unit, University of Birmingham, received support from the UK Department of Health up to March 2012. Catherine Sackley was supported by a NIHR senior investigator award, Collaboration for Leadership in Applied Health Research and Care East of England and West Midlands Strategic Health Authority Clinical Academic Training award.



ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.058

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [nhredit@southampton.ac.uk](mailto:nhredit@southampton.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/hta>

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 07/01/07. The contractual start date was in January 2009. The draft report began editorial review in April 2014 and was accepted for publication in February 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2016. This work was produced by Clarke *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## **Health Technology Assessment Editor-in-Chief**

**Professor Hywel Williams** Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

## **NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley** Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

## **NIHR Journals Library Editors**

**Professor Ken Stein** Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May** Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key** Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke** Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Ms Tara Lamont** Scientific Advisor, NETSCC, UK

**Professor Elaine McColl** Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

**Professor John Norrie** Health Services Research Unit, University of Aberdeen, UK

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:  
[www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [nihredit@southampton.ac.uk](mailto:nihredit@southampton.ac.uk)